ATE349446T1 - Amyloid plaque aggregationshemmer und diagnostische bilderzeugungsmittel - Google Patents

Amyloid plaque aggregationshemmer und diagnostische bilderzeugungsmittel

Info

Publication number
ATE349446T1
ATE349446T1 AT02728893T AT02728893T ATE349446T1 AT E349446 T1 ATE349446 T1 AT E349446T1 AT 02728893 T AT02728893 T AT 02728893T AT 02728893 T AT02728893 T AT 02728893T AT E349446 T1 ATE349446 T1 AT E349446T1
Authority
AT
Austria
Prior art keywords
diagnostic imaging
imaging agents
amyloid plaque
aggregation inhibitors
plaque aggregation
Prior art date
Application number
AT02728893T
Other languages
English (en)
Inventor
Hank F Kung
Mei-Ping Kung
Zhi-Ping Zhuang
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Application granted granted Critical
Publication of ATE349446T1 publication Critical patent/ATE349446T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
    • C07F13/005—Compounds without a metal-carbon linkage
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0468—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/22—Tin compounds
    • C07F7/2208—Compounds having tin linked only to carbon, hydrogen and/or halogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT02728893T 2001-04-23 2002-04-23 Amyloid plaque aggregationshemmer und diagnostische bilderzeugungsmittel ATE349446T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28528201P 2001-04-23 2001-04-23

Publications (1)

Publication Number Publication Date
ATE349446T1 true ATE349446T1 (de) 2007-01-15

Family

ID=23093574

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02728893T ATE349446T1 (de) 2001-04-23 2002-04-23 Amyloid plaque aggregationshemmer und diagnostische bilderzeugungsmittel

Country Status (12)

Country Link
US (5) US6696039B2 (de)
EP (1) EP1381604B1 (de)
JP (1) JP4317955B2 (de)
KR (1) KR20040058111A (de)
CN (1) CN100422180C (de)
AT (1) ATE349446T1 (de)
AU (1) AU2002258915B2 (de)
CA (1) CA2444214A1 (de)
DE (1) DE60217090T2 (de)
ES (1) ES2274973T3 (de)
TW (1) TWI245764B (de)
WO (1) WO2002085903A2 (de)

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7544511B2 (en) * 1996-09-25 2009-06-09 Neuralstem Biopharmaceuticals Ltd. Stable neural stem cell line methods
GB0018473D0 (en) * 2000-07-27 2000-09-13 Merck Sharp & Dohme Therapeutic agents
SI1334091T1 (sl) 2000-08-24 2013-01-31 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Derivati tioflavina in njihova uporaba pri diagnozi in terapiji pri Alzheimerjevi bolezni
US7270800B2 (en) 2000-08-24 2007-09-18 University Of Pittsburgh Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition
KR20040058111A (ko) * 2001-04-23 2004-07-03 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 아밀로이드 플라크 응집 억제제 및 진단 영상화제
CA2474411A1 (en) * 2002-02-13 2003-08-21 Amersham Plc Benzothiazole derivatives for in vivo imaging of amyloid plaques
US8293488B2 (en) 2002-12-09 2012-10-23 Neuralstem, Inc. Method for screening neurogenic agents
EP1576134B1 (de) 2002-12-09 2013-03-06 Judith Kelleher-Andersson Verfahren zur entdeckung neurogener wirkstoffe
CN1774267A (zh) * 2003-01-22 2006-05-17 综合医院有限公司 与淀粉样物质结合的金属螯合剂
ES2393921T3 (es) * 2003-03-14 2013-01-02 University Of Pittsburgh - Of The Commonwealthsystem Of Higher Education Compuestos derivados de BENZOTIAZOL, composiciones y usos
CA2438032C (en) * 2003-03-14 2013-05-07 University Of Pittsburgh Benzothiazole derivative compounds, compositions and uses
GB0307855D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Organic compounds
WO2004100998A2 (en) 2003-05-07 2004-11-25 General Electric Company Compositions and methods for non-invasive imaging of soluble beta-amyloid
US8236282B2 (en) 2003-08-22 2012-08-07 University of Pittsburgh—of the Commonwealth System of Higher Education Benzothiazole derivative compounds, compositions and uses
US20050049487A1 (en) * 2003-08-26 2005-03-03 Johnson Bruce Fletcher Compounds and kits for preparing imaging agents and methods of imaging
US9017724B2 (en) 2004-02-24 2015-04-28 The General Hospital Corporation Catalytic radiofluorination
US8257680B1 (en) 2004-02-24 2012-09-04 The General Hospital Corporation Catalytic radiofluorination
US8097654B2 (en) * 2004-03-18 2012-01-17 Suntory Holdings Limited Radiolabeled 3-[3-(benzoyl-amido)benzyloxy]aspartic acid derivative and method of producing the same
JP2008505115A (ja) 2004-07-02 2008-02-21 ユニバーシティー オブ ピッツバーグ 抗アミロイド治療の有効性に対する代用マーカーとしてのアミロイドイメージング
CN102327626A (zh) * 2004-07-02 2012-01-25 匹兹堡大学高等教育联邦体系 诊断淀粉样蛋白沉积相关疾病的前驱形式的方法
US7803351B2 (en) * 2004-08-20 2010-09-28 Washington University Blood brain barrier permeation peptides
US7691629B2 (en) 2004-11-17 2010-04-06 Neuralstem, Inc. Transplantation of human neural cells for treatment of neurodegenerative conditions
US20070031328A1 (en) * 2005-06-24 2007-02-08 Kung Hank F Radiolabeled-pegylation of ligands for use as imaging agents
US7666886B2 (en) * 2005-07-15 2010-02-23 The Regents Of The University Of California Compounds and methods for the diagnosis and treatment of amyloid associated diseases
US7709468B2 (en) 2005-09-02 2010-05-04 Abbott Laboratories Imidazo based heterocycles
WO2007033080A2 (en) * 2005-09-12 2007-03-22 Emory University Alzheimer's disease imaging agents
CA2627722A1 (en) † 2005-10-31 2007-06-21 Merck & Co., Inc. Cetp inhibitors
WO2007063946A1 (ja) 2005-11-30 2007-06-07 Fujifilm Ri Pharma Co., Ltd. アミロイドの凝集及び／又は沈着に起因する疾患の診断薬及び治療薬
US20090281120A1 (en) * 2005-12-12 2009-11-12 Ono Pharmaceutical Co., Ltd Bicyclic heterocyclic compound
WO2007078335A2 (en) * 2005-12-21 2007-07-12 Decode Genetics, Ehf. Biaryl nitrogen heterocycle inhibitors of lta4h for treating inflammation
TW200736252A (en) 2006-01-27 2007-10-01 Astrazeneca Ab Novel heteroaryl substituted benzothiazoles
TW200803903A (en) 2006-04-28 2008-01-16 Nihon Mediphysics Co Ltd Novel compound having affinity to amyloid
US7700616B2 (en) * 2006-05-08 2010-04-20 Molecular Neuroimaging, Llc. Compounds and amyloid probes thereof for therapeutic and imaging uses
AU2007252658B2 (en) * 2006-05-19 2012-03-29 Nihon Medi-Physics Co., Ltd. Novel compound having affinity for amyloid
TW200813035A (en) 2006-06-19 2008-03-16 Astrazeneca Ab Novel heteroaryl substituted benzoxazoles
US8277777B2 (en) 2006-06-21 2012-10-02 Nihon Medi-Physics Co., Ltd. Compound having affinity for amyloid
EP2080526A4 (de) * 2006-11-09 2012-11-07 Nihon Mediphysics Co Ltd Radioaktives diagnostisches abbildungsagens
AU2007320581A1 (en) * 2006-11-17 2008-05-22 Nihon Medi-Physics Co., Ltd. Novel compounds with affinity for amyloid
CN101595108A (zh) * 2006-11-30 2009-12-02 日本医事物理股份有限公司 对淀粉状蛋白具有亲和性的新化合物
EP2125800A1 (de) * 2007-01-22 2009-12-02 AstraZeneca AB Neuartige heteroaryl-substituierte imidazo[1,2-a]-pyridinderivate
JP5258583B2 (ja) 2007-02-13 2013-08-07 日本メジフィジックス株式会社 放射性画像診断剤の製造方法
EP1964840A1 (de) 2007-02-28 2008-09-03 sanofi-aventis Imidazo[1,2-a]pyridine und deren pharmazeutische Verwendung
TW200901998A (en) 2007-03-06 2009-01-16 Astrazeneca Ab Novel 2-heteroaryl substituted benzothiophenes and benzofuranes
MX2009009113A (es) * 2007-03-06 2009-09-04 Astrazeneca Ab Nuevos indoles 2-heteroaril sustituidos 695.
FR2913886B1 (fr) * 2007-03-22 2012-03-02 Guerbet Sa Utilisation de nanoparticules metalliques dans le diagnostique de la maladie d'alzheimer
WO2008134618A2 (en) * 2007-04-27 2008-11-06 The General Hospital Corporation Novel imaging tracers for early detection and treatment of amyloid plaques caused by alzheimer's disease and related disorders
AU2008314870A1 (en) * 2007-10-24 2009-04-30 Nihon Medi-Physics Co., Ltd. Novel compound having affinity for amyloid
AU2008314871A1 (en) 2007-10-26 2009-04-30 Nihon Medi-Physics Co., Ltd. Novel compound having affinity for amyloid
TW200922629A (en) * 2007-10-30 2009-06-01 Nihon Mediphysics Co Ltd Utilization of novel compounds with amyloid affinity and method of producing the same
EP2216051A1 (de) * 2007-10-30 2010-08-11 Nihon Medi-Physics Co., Ltd. Verwendung einer neuen verbindung mit affinität für amyloid und verfahren zu ihrer herstellung
AU2008319985A1 (en) * 2007-10-30 2009-05-07 Nihon Medi-Physics Co., Ltd. Use of novel compound having affinity for amyloid, and process for production of the same
CN102702195A (zh) * 2007-10-30 2012-10-03 日本医事物理股份有限公司 对淀粉样蛋白具有亲和性的新化合物的应用及制备方法
US8932557B2 (en) 2008-02-14 2015-01-13 Eli Lilly And Company Imaging agents for detecting neurological dysfunction
WO2009102498A1 (en) 2008-02-14 2009-08-20 Siemens Medical Solutions Usa, Inc. Novel imaging agents for detecting neurological dysfunction
US20100331676A1 (en) * 2008-02-27 2010-12-30 Avid Radiopharmaceuticals, Inc. Gamma probe detection of amyloid plaque using radiolabeled a-beta binding compounds
EP3231804B1 (de) 2008-03-21 2021-03-03 The General Hospital Corporation Verbindungen und zusammensetzungen für den nachweis und die behandlung von morbus alzheimer und verwandten erkrankungen
US8557222B2 (en) * 2008-04-04 2013-10-15 Avid Radiopharmaceuticals, Inc. Radiopharmaceutical imaging of neurodegenerative diseases
US8409419B2 (en) 2008-05-21 2013-04-02 Paul R. Kruesi Conversion of carbon to hydrocarbons
WO2009146388A1 (en) 2008-05-28 2009-12-03 The Trustees Of Columbia University In The City Of New York Voxel-based methods for assessing subjects using positron emission tomography
AU2009260526A1 (en) * 2008-05-30 2009-12-23 Merck Sharp & Dohme Corp. Novel substituted indoles
EP2300481B1 (de) * 2008-05-30 2015-09-30 Merck Sharp & Dohme Corp. Neue substituierte azabenzoxazole
CN102047061A (zh) * 2008-05-30 2011-05-04 福斯特韦勒能源股份公司 通过氧化燃料燃烧发电的方法和系统
JP2011529086A (ja) 2008-07-24 2011-12-01 シーメンス メディカル ソリューションズ ユーエスエー インコーポレイテッド Ａｄ病変を同定するために有用な造影剤
EP2344877A4 (de) * 2008-09-30 2014-09-10 Univ Case Western Reserve Molekularsonden zur bildgebung von myelin
JP2012508889A (ja) * 2008-11-13 2012-04-12 アビッド レディオファーマシューティカルズ、インク． 神経変性疾患の検出と診断のためのヒストグラムに基づいた分析方法
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
EP2218464A1 (de) * 2009-02-11 2010-08-18 Technische Universität München Verbindungen zur nichtinvasiven Messung von Aggregaten von Amyloidpeptiden
FR2942227B1 (fr) 2009-02-13 2011-04-15 Guerbet Sa Utilisation de tampons pour la complexation de radionucleides
US8691187B2 (en) 2009-03-23 2014-04-08 Eli Lilly And Company Imaging agents for detecting neurological disorders
CA2756137C (en) * 2009-03-23 2015-11-24 Siemens Medical Solutions Usa, Inc. Imaging agents for detecting neurological disorders
CU23844B1 (es) 2009-04-17 2012-10-15 Ct De Neurociencias De Cuba Procedimiento de obtención de nuevos derivados de naftaleno para el diagnóstico in vivo de la enfermedad de alzheimer
JP5073871B2 (ja) * 2010-03-01 2012-11-14 日本メジフィジックス株式会社 放射性ヨウ素標識有機化合物またはその塩
CA2806904C (en) 2010-07-28 2018-11-27 Neuralstem, Inc. Methods for treating and/or reversing neurodegenerative diseases and/or disorders
US9259495B2 (en) 2010-10-12 2016-02-16 Mayo Foundation For Medical Education And Research Imaging of meningiomas using phenylbenzothiazole, stilbene, or biphenylalkyne derivatives
MX2013005545A (es) * 2010-11-16 2013-08-01 Ge Healthcare Ltd Compuestos heterociclicos como sodas de imagenologia de la patologia tau.
FR2968999B1 (fr) 2010-12-20 2013-01-04 Guerbet Sa Nanoemulsion de chelate pour irm
TWI528977B (zh) 2011-05-20 2016-04-11 Nihon Mediphysics Co Ltd New amyloid affinity products
EP2725027B1 (de) 2011-06-24 2017-03-01 Nihon Medi-Physics Co., Ltd. Neue verbindungen mit amyloidaffinität
FR2980364B1 (fr) 2011-09-26 2018-08-31 Guerbet Nanoemulsions et leur utilisation comme agents de contraste
US20140335019A1 (en) * 2011-12-02 2014-11-13 The Regents Of The University Of Michigan Compositions and methods for the treatment and analysis of neurological disorders
US20150157744A1 (en) 2012-06-27 2015-06-11 Geoffrey B. Johnson Treatment of meningiomas using phenylbenzothiazole, stilbene, biphenylalkyne, or pyridine derivatives
EP2911664B1 (de) 2012-10-25 2019-05-08 The General Hospital Corporation Kombinationstherapien zur behandlung von morbus alzheimer und verwandten erkrankungen
US10058530B2 (en) 2012-10-25 2018-08-28 The General Hospital Corporation Combination therapies for the treatment of Alzheimer's disease and related disorders
CN103073520B (zh) * 2012-12-24 2014-10-08 湖南大学 一种合成2-苯基苯并噻唑及其衍生物的方法
FR3001154B1 (fr) 2013-01-23 2015-06-26 Guerbet Sa Magneto-emulsion vectorisee
EP2953970A4 (de) 2013-02-08 2016-06-29 Misfolding Diagnostics Inc Transthyretinantikörper und verwendungen davon
RU2015147450A (ru) 2013-04-29 2017-06-05 Ф. Хоффманн-Ля Рош Аг ПРОИЗВОДНЫЕ 2-ФЕНИЛ ИЛИ 2-ГЕТЕРОАРИЛ ИМИДАЗОЛ[1,2-a]ПИРИДИНА
US10525005B2 (en) 2013-05-23 2020-01-07 The General Hospital Corporation Cromolyn compositions and methods thereof
JP6182668B2 (ja) * 2013-09-26 2017-08-16 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 画像化ツールとしてのイミダゾ［１，２−ａ］ピリジン−７−アミン
AU2014340182B2 (en) 2013-10-22 2019-05-23 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
AU2015336194B2 (en) 2014-10-20 2019-01-03 Neuralstem, Inc. Stable neural stem cells comprising an exogenous polynucleotide coding for a growth factor and methods of use thereof
RU2721845C2 (ru) * 2015-12-30 2020-05-25 Нойборон Медтех Лтд. СОЕДИНЕНИЕ ДЛЯ СПЕЦИФИЧЕСКОГО СВЯЗЫВАНИЯ С β-АМИЛОИДОМ
CN108187044B (zh) * 2015-12-30 2021-03-09 南京中硼联康医疗科技有限公司 用于消除β淀粉样蛋白的中子捕获治疗系统
CA3033079A1 (en) 2016-08-31 2018-03-08 The General Hospital Corporation Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases
KR20210070232A (ko) 2017-07-20 2021-06-14 아즈테라피즈 인코포레이티드 크로몰린 나트륨 및 이부프로펜의 분말화된 제형
JP6831802B2 (ja) * 2018-01-12 2021-02-17 上海富吉医療器械有限公司Ｓｈａｎｇｈａｉ Ｃｈａｒｔｗｅｌｌ Ｍｅｄｉｃａｌ Ｉｎｓｔｒｕｍｅｎｔ Ｃｏ．， Ｌｔｄ． 放射性核種標識化合物及びこれを含有するイメージング剤
WO2020007822A1 (en) 2018-07-02 2020-01-09 Conservatoire National Des Arts Et Metiers (Cnam) Bismuth metallic (0) nanoparticles, process of manufacturing and uses thereof
CA3105392A1 (en) 2018-07-02 2020-01-09 The General Hospital Corporation Powdered formulations of cromolyn sodium and .alpha.-lactose
EP3893945A4 (de) 2018-12-10 2022-11-30 The General Hospital Corporation Cromolynester und verwendungen davon
US12458622B2 (en) 2020-04-06 2025-11-04 The General Hospital Corporation Methods of treatment of coronavirus-induced inflammation conditions
KR102240400B1 (ko) 2020-11-19 2021-04-15 한국원자력연구원 베타-아밀로이드 검출용 수용성 화합물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9317949D0 (en) 1993-08-28 1993-10-13 Stevens Malcolm F G Benzothiazole compounds
US5552415A (en) * 1993-12-21 1996-09-03 Eli Lilly And Company Method of inhibiting Alzheimer's Disease
US6417178B1 (en) 1994-07-19 2002-07-09 University Of Pittsburgh Amyloid binding nitrogen-linked compounds for the antemortem diagnosis of alzheimer's disease, in vivo imaging and prevention of amyloid deposits
US6168776B1 (en) 1994-07-19 2001-01-02 University Of Pittsburgh Alkyl, alkenyl and alkynyl Chrysamine G derivatives for the antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition
US6054114A (en) * 1996-05-08 2000-04-25 Massachusetts Institute Of Technology Organometallic ligands for the localization and quantification of amyloid in vivo and in vitro
AU4988997A (en) 1996-10-23 1998-05-15 Osteoscreen, Inc. Compositions and methods for treating bone deficit conditions
US5869500A (en) 1996-12-13 1999-02-09 Hoffmann-La Roche Inc. Pyridone compounds useful in treating Alzheimer's disease
US6037473A (en) 1997-11-13 2000-03-14 Haarmann & Reimer Gmbh Use of substituted benzazoles as UV absorbers, new benzazoles and processes for their preparation
KR20040058111A (ko) * 2001-04-23 2004-07-03 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 아밀로이드 플라크 응집 억제제 및 진단 영상화제

Also Published As

Publication number Publication date
JP2005512945A (ja) 2005-05-12
EP1381604A2 (de) 2004-01-21
JP4317955B2 (ja) 2009-08-19
USRE44354E1 (en) 2013-07-09
ES2274973T3 (es) 2007-06-01
EP1381604B1 (de) 2006-12-27
DE60217090T2 (de) 2007-07-12
US7425318B2 (en) 2008-09-16
TWI245764B (en) 2005-12-21
US20060051293A1 (en) 2006-03-09
CA2444214A1 (en) 2002-10-31
KR20040058111A (ko) 2004-07-03
WO2002085903A2 (en) 2002-10-31
US20030059369A1 (en) 2003-03-27
US6696039B2 (en) 2004-02-24
DE60217090D1 (de) 2007-02-08
AU2002258915B2 (en) 2007-11-15
CN1620454A (zh) 2005-05-25
CN100422180C (zh) 2008-10-01
US20040131545A1 (en) 2004-07-08
US6946116B2 (en) 2005-09-20
USRE44338E1 (en) 2013-07-02
WO2002085903A3 (en) 2003-02-27

Similar Documents

Publication Publication Date Title
ATE349446T1 (de) Amyloid plaque aggregationshemmer und diagnostische bilderzeugungsmittel
MX2007007380A (es) Derivados de estilbeno y su uso para estudios de union y por imagenes de placas amiloides.
CY1107383T1 (el) Αναστολεις της φωσφολιπασης α2 του κυτοπλασμικου διαλυματος
DE60126980D1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
CY1108725T1 (el) Συνδυασμος ανταγωνιστου-nmda και αναστολεων ακετυλοχολινεστερασης δια την θεραπειαν της νοσου alzheimer
MXPA04008068A (es) Metodo para administrar moleculas de glp-1.
DK1472541T3 (da) Afbildningsmidler og metoder til at afbilde NAALADase og PSMA
BRPI0411743A (pt) método e composições para tratar doenças relacionadas a amilóides
ATE439868T1 (de) Targetingmittel für molekulare bilderzeugung
TW200716673A (en) Use of TNF &ahr; inhibitor for treatment of erosive polyarthritis
CY1112238T1 (el) Αναστολεις μιτωτικης κινεσινης και μεθοδοι χρησης αυτων
EE04911B1 (et) Ühend ja farmatseutiline kompositsioon proteaasi inhibiitoritena, nende kasutamine ning meetod selle ühendi valmistamiseks
DE60137337D1 (de) Vorbeugende und therapeutsche monoklonale antikörper gegen vacciniavirusantigene
WO2007033080A3 (en) Alzheimer's disease imaging agents
DE60312736D1 (de) 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems
BR0316458A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto
ATE433331T1 (de) Kontrastmittel für die magnetresonanztomographie und entsprechende verfahren
ATE497763T1 (de) Verfahren und reagenzien zur behandlung von entzündlichen erkrankungen
DK1553985T3 (da) Biphenyler som billeddannelsesmiddel i forbindelse med Alzheimers sygdom
WO2006078384A3 (en) Stilbene derivatives and their use
DK1353948T3 (da) Oplöselige biologiske analoge til bata-amyloidpeptid
SE0002729D0 (sv) Novel compound form
DE60134735D1 (de) Neue neurokinin-antagonisten zum gebrauch als arzneimittel
JO3446B1 (ar) طريقة لمعالجة الأرق الأولي
NO20025124D0 (no) Metode

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1381604

Country of ref document: EP

REN Ceased due to non-payment of the annual fee